Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

Phase 2 Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD) 

Several preliminary studies suggest that cannabis may treat PTSD symptoms. Building off of our previous MJP1 study, this current study aims to re-examine use of inhaled cannabis for treatment of PTSD using a larger sample size, a parallel design, and methods to mitigate placebo response. This Phase 2 multicenter randomized placebo-controlled, double-blind study will assess the safety and efficacy of inhaled cannabis (high THC) versus placebo to manage PTSD symptoms and pain among approximately 320 Veterans in an outpatient setting. The study will be conducted in Michigan and three other sites in the U.S..